GeneDx Slashes 2026 Revenue Forecast by Over 10%, Shares Plunge 41% Premarket
Summary
GeneDx Holdings Corp. announced a significant reduction to its full-year 2026 revenue forecast, now projecting $475 million to $490 million, down from a previous range of $540 million to $555 million. This follows the company's Q1 2026 earnings report yesterday, which revealed a wider-than-anticipated net loss of $63.3 million and revenue of $102.3 million, both missing analyst estimates. Additionally, Q2 guidance for adjusted loss and revenue also fell short of expectations. The substantial cut to the annual revenue outlook, representing a material downgrade to future growth prospects, has triggered a sharp negative market reaction, with shares plummeting 41% in premarket trading. This revised guidance indicates a more moderate growth in test volumes than previously anticipated, raising concerns about the company's near-term financial performance. Traders will be watching for further details on test volume trends and the company's path to profitability.
At the time of this announcement, WGS was trading at $39.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $55.17 to $170.87. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.